Danaher achieves FDA clearance for Masimo feature, shares steady on NYSE

Danaher achieves FDA 510(k) clearance for a Masimo opioid-related monitoring feature, adding a fresh regulatory milestone to its health-care portfolio while the NYSE-listed shares trade close to 178 dollars.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 11:55.

Danaher Corp. (US2358511028) has secured a fresh regulatory milestone in the United States. A Masimo unit within the group obtained FDA 510(k) clearance for a new feature on its wearable Radius VSM monitor, according to a June 22 report, while the Danaher shares trade on the NYSE around 178 dollars. Gurufocus summary of the FDA clearance

FDA approves opioid risk monitoring

On June 22, 2026, Masimo, a subsidiary of Danaher, received FDA 510(k) approval for a feature that detects opioid-induced respiratory depression in patients using the Radius VSM wearable monitor, enhancing safety for individuals at risk of opioid-related breathing issues. Detailed Gurufocus report on the Masimo feature

The approval concerns a continuous monitoring capability embedded in Radius VSM, which adds algorithmic detection of respiratory compromise linked to opioid use and can trigger timely clinical responses in hospital and post-acute settings. Gurufocus description of the device and feature The device extends Danaher’s presence in advanced patient-monitoring solutions, aligning with regulators’ focus on opioid safety in the US health-care system.

Analyst view and valuation backdrop

Danaher’s equity footprint remains anchored on the NYSE under the ticker DHR, with a market capitalization around 125 to 126 billion dollars as of late June 2026, underlining its position among large-cap US health-care and life-science suppliers. Tradingkey profile of Danaher The shares recently closed near 178.29 dollars, for a trailing price-earnings ratio of roughly 34 based on EPS around 5.07 dollars. Tradingkey snapshot of price, EPS and valuation

Consensus data compiled on Tradingkey indicate that analysts broadly rate the Danaher stock as a Buy, with an average price target around 240 dollars, signalling that the sell-side expects further upside from the current price region over their stated horizon. Tradingkey consensus rating and target for DHR Recent insider activity reported by Gurufocus shows approximately 0.2 million dollars of share sales over the past three months, which the outlet interprets as cautious sentiment among insiders rather than aggressive accumulation. Gurufocus note on recent insider transactions

How Danaher earns its money

Danaher generates revenues primarily from specialized health-care, diagnostics and industrial technologies, and Masimo’s Radius VSM wearable monitor for continuous patient surveillance illustrates this focus on high-value medical devices. The feature cleared by the FDA sits within Danaher’s broader portfolio of monitoring systems and diagnostic tools used by hospitals and clinics worldwide, complementing its established franchises in life-science instrumentation and analytical solutions. Gurufocus overview of Danaher’s health-care activities

Where the stock trades today

Danaher shares (US2358511028) most recently traded on the NYSE at around 178.29 dollars per share as of the close on 2026-06-22, with a reported market capitalization near 126.18 billion dollars. Tradingkey closing price and market-cap data

Danaher in key figures

• Company: Danaher Corporation
• ISIN: US2358511028
• WKN: 866197
• Ticker: DHR
• Trading venue: NYSE
• Price (as of 2026-06-22, 16:00): 178.29 USD
• Market cap: 126.18 billion USD (as of 2026-06-22)
• Sector / industry: Health Care Equipment & Life Sciences
• Index membership: S&P 500
• Next earnings date: not officially scheduled

Disclaimer: This text is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or a solicitation of any transaction. All data have been compiled from publicly available sources believed to be reliable, but their accuracy and completeness cannot be guaranteed.